Quick Answer
Adicet Bio, Inc. reported Operating Income Loss of -$122.11 million for the year ending 2025.
- Adicet Bio, Inc. showed an increase of +4.3% in Operating Income Loss from 2024 to 2025.
- This data is from Adicet Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$3.36 million | Q2 2017: -$4.06 million | Q3 2017: -$3.95 million | Q4 2017: -$7.52 million | Q1 2018: -$10.20 million | Q2 2018: -$14.11 million | Q3 2018: -$9.03 million | Q4 2018: -$6.36 million | Q1 2019: -$11.69 million | Q2 2019: -$19.17 million | Q3 2019: -$15.23 million | Q4 2019: -$29.44 million | Q1 2020: -$7.56 million | Q2 2020: -$8.63 million | Q3 2020: -$13.66 million | Q1 2021: -$21.35 million | Q2 2021: -$10.83 million | Q3 2021: -$13.71 million | Q1 2022: $4.71 million | Q2 2022: -$22.71 million | Q3 2022: -$22.99 million | Q1 2023: -$33.32 million | Q2 2023: -$34.89 million | Q3 2023: -$52.26 million | Q1 2024: -$30.87 million | Q2 2024: -$32.85 million | Q3 2024: -$33.15 million | Q1 2025: -$29.89 million | Q2 2025: -$32.39 million | Q3 2025: -$27.95 million.
- Over the full 9 years of available data (2017 to 2025), Adicet Bio, Inc.'s Operating Income Loss has declined by 546.7%.
- Historical annual values: Fiscal year 2025: -$122.11 million | Fiscal year 2024: -$127.62 million | Fiscal year 2023: -$152.04 million | Fiscal year 2022: -$72.55 million | Fiscal year 2021: -$61.43 million | Fiscal year 2020: -$39.19 million | Fiscal year 2019: -$31.39 million | Fiscal year 2018: -$14.96 million | Fiscal year 2017: -$18.88 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: